| FIX |
Report |
Q2 2026 Diluted EPS |
BEAT |
pred ~$11.20 vs. cons $10.40 |
MEDIUM |
| FIX |
Report |
Q2 2026 Revenue |
BEAT |
pred ~$3.05B vs. cons $2.94B |
MEDIUM |
| FIX |
Report |
Q2 2026 Gross Margin |
BEAT |
pred ~25.3% vs. cons ~24.7% (implied core level) |
LOW |
| FIX |
Guide |
FY2026 same-store revenue growth guidance |
UNCHANGED |
guide ~mid-to-high 20s% (27%) vs. cons ~25% (FY2026) |
MEDIUM |
| FIX |
Guide |
Book-to-bill / backlog momentum (Q2) |
LOWER |
guide/implied ~1.1x book-to-bill vs. cons expectation ~1.2x (Q2 2026) |
LOW |
| FIX |
Guide |
FY2026 gross margin range commentary |
UNCHANGED |
guide ~25% 'strong range' vs. cons ~24.5% modeled (FY2026) |
MEDIUM |
| FIX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| FIX |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Headline beat likely driven by continued backlog conversion and volume, but with Q1's $43M one-time change-order benefit absent, analysts will re-anchor FY26 estimates toward 'core' ~25% gross margin rather than Q1's 26.3% headline, capping forward EPS revisions even after a beat. Combined with book-to-bill normalizing off record highs, tougher H2 same-store comps already flagged by management, a recent leadership reshuffle, an analyst downgrade, and heavy insider selling into a rich (~35x forward) multiple, the setup favors an initial relief pop that partially fades over the week as the market digests implicit margin/backlog deceleration rather than sustained follow-through buying. |
LOW |